Key Insights

Highlights

Related Conditions

Often studied with 9 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

Trial Status

Recruiting1

Clinical Trials (1)

Research Network

Active Sponsors

  • University of Rochester1

Top Investigators

Related Conditions

  • Neuronal Ceroid Lipofuscinosis Cln21
  • Neuronal Ceroid Lipofuscinosis Cln51
  • Neuronal Ceroid Lipofuscinosis Cln31
  • Neuronal Ceroid Lipofuscinosis1
  • Neuronal Ceroid Lipofuscinosis Cln81

Activity Timeline